CDEK
← All drugs Report issue

vimseltinib

Small moleculeapproved

Approved

Feb 14, 2025

Clinical trial activity

6 trials · 2 clinical orgs · 1 marketing orgs

Phase 1
4
Phase 2
2
Phase 3
1
Phase 4
0

Earliest trial started Feb 16, 2017 (NCT03069469)

Timeline

2010s

  1. Jan 1, 2017

    Deciphera Pharmaceuticals LLC — Earliest Phase 1 Sponsor(trial)

2020s

  1. Jan 1, 2021

    Deciphera Pharmaceuticals LLC — Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2024

    Deciphera Pharmaceuticals LLC — Earliest Phase 2 Sponsor(trial)

  3. Feb 14, 2025

    Earliest FDA Approval

  4. Feb 14, 2025

    Deciphera Pharmaceuticals LLC — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedPriority reviewFeb 14, 2025

Chemistry & pharmacology

Loading structure…

SMILES

Cc1nc(-c2cnc(NC(C)C)n(C)c2=O)ccc1Oc1ccnc(-c2cnn(C)c2)c1
Mol. weight
431.5 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • dcc-3014

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07158411Phase 1Nov 20, 2025Deciphera Pharmaceuticals LLC
NCT07158398Phase 1Oct 31, 2025Deciphera Pharmaceuticals LLC
NCT06619561Phase 2Dec 31, 2024Deciphera Pharmaceuticals LLC
NCT05059262Phase 3Oct 14, 2021Deciphera Pharmaceuticals LLC
NCT04242238Phase 1Jan 22, 2020Memorial Sloan-Kettering Cancer Center
NCT03069469Phase 1Feb 16, 2017Deciphera Pharmaceuticals LLC
Showing 6 of 6 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Deciphera Pharmaceuticals LLCFor profit5532017
Memorial Sloan-Kettering Cancer CenterAcademic/Hospital1112020
2 organizations
Page 1 / 1

Marketing (1)

OrganizationOrg typeRelationshipDate
Deciphera Pharmaceuticals LLCFor profitMKTGFeb 14, 2025